Synthesis and SAR of a novel, potent and structurally simple LTD4 antagonist of the quinoline class

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 8, 1998, Pages 965-970

  Von Sprecher, Andreas ^a   Gerspacher, Marc ^a   Beck, Andreas ^a   Kimmel, Sabine ^a   Wiestner, Hansruedi ^a   Anderson, Gary P ^a   Niederhauser, Ulrich ^a   Subramanian, Natarajan ^a   Bray, Michael A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antagonists; Leukotrienes

Indexed keywords

2,2 DIETHYL 4 [3 (7 FLUORO 2 QUINOLINYLMETHOXY)ANILINO] 4 OXOBUTYRIC ACID; 4 [3 (7 FLUORO 2 QUINOLINYLMETHOXY)PHENYLAMINO] 2,2 DIETHYL 4 OXO BUTANOIC ACID; DRUG ANALOG; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; QUINOLINE DERIVATIVE; SUCCINIC ACID; UNCLASSIFIED DRUG; ZAFIRLUKAST;

ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-ASTHMATIC AGENTS; BIOLOGICAL AVAILABILITY; BRONCHOCONSTRICTION; CALLITHRIX; GUINEA PIGS; INDICATORS AND REAGENTS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE D4; LEUKOTRIENE E4; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; QUINOLINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032554711     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00137-1     Document Type: Article

References (16)

1. [1] Ford-Hutchinson AW. Leukotriene antagonists and inhibitors: clinical applications. Adv. Prostagandin, Thromboxane, and Leukotriene Res. 1995; 23: 69-74.
2. [2] Brooks CDW, Summers JB. Modulators of leukotriene biosynthesis and receptor activation J. Med. Chem. 1996; 39: 2629-2654.
3. [3] von Sprecher A, Beck A, Gerspacher M, Sallmann A, Anderson GP, Subramanian N, Niederhauser U, Bray MA. Strategies in the design of peptidoleukotriene antagonists. J Lipid Mediators 1993; 6 (1-3): 265-73.
4. [4] von Sprecher A, Beck A, Gerspacher M, Bray MA. Peptidoleukotriene antagonists: state of the art. Chimia 1992; 46: 304-311.
5. 4. 1. Synthesis and structure-activity relationships. J. Med. Chem. 1988; 31: 84-2654.
6. [6] Brown FJ. Discovery of Accolate™ (ICI 204,219), a peptide leukotriene antagonist for asthma. In: Merluzzi VJ, Adams J, editors. The Search for Anti-Inflammatory Drugs. Boston: Birkhäuser Boston, 1995: 161-189.
7. 4 receptor antagonist devoid of peroxisomal enzyme induction. Bioorg. Med. Chem. Lett. 1995; 5: 283-288.
8. 4 with special emphasis on CGP45715A. Drugs Fut. 1991; 16: 827-843.
9. [9] Galemmo RA, Gavai A, Huang F-C. Recent developments in sulphidopeptide leukotriene receptor antagonists. Curr. Opin Ther. Patents. 1992; 811-833.
10. [10] Musser JH, Kreft AF. Substituted-[2-quinolinyl(bridged)aryl] compounds: modulators of eicosanoid biosynthesis and action. Drugs Fut. 1990; 15: 73-80.
11. [11] von Sprecher A, Gerspacher M, Beck A, Anderson GP, Niederhauser U, Subramanian N, Ball HA, Gentsch C, Vassout A, Felner A, Bittiger H, Hauser K, Giese K, Kraetz J, Bray MA. CGP57698: a structurally simple, highly potent peptidoleukotriene (pLT) antagonist of the quinoline type. In: Sinzinger H, Vane JR, Samuelsson B, Paoletti R, Ramwell PW, Wong PY-K, editors. Recent Advances in Prostaglandin, Thromboxane, and Leukotriene Research. New York: Plenum Publishing Corporation, 1998: 169-172, in press.
12. [12] Rang HP. Br. J. Pharmacol. Chemother. 1964; 22: 356.
13. [13] Pong SS, De Haven RN. Proc. Natl. Acad. Sci. U.S.A. 1983; 80: 7415.
14. [14] Amdur MO, Meade J. Am. J. Physiol. 1958; 192: 364.
15. [15] Song Z, Mertzman M, Hughes DL. Improved synthesis of quinaldines by the Skraup reaction. J. Heterocyclic Chem. 1993; 30: 17-21.
16. [16] Le Moal H, Foucaud A, Carrié R, Danion D, Fayat C. No 152.-Recherches sur la structure et les propriétés physicochimiques des acides succiniques dissymétriquement substitués. II.-Préparation des esters-acides et diesters succiniques mono et α,α-disubstitué.s. Bull. Soc. chim. 1964; 828-830.